Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria
Autor: | Martin Füchtenbusch, Wolfgang Kerner, Joachim Rosenbauer, Andreas Knauerhase, Jochen Seufert, Reinhard W. Holl, F Best, Martin Hofer, Hans-Peter Kempe, Peter M. Jehle, Barbara Bohn |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes Hypoglycemia 03 medical and health sciences Young Adult 0302 clinical medicine Endocrinology Diabetes mellitus Internal medicine Germany Internal Medicine Medicine Humans Hypoglycemic Agents 030212 general & internal medicine Registries Young adult Type 1 diabetes business.industry Insulin Confounding nutritional and metabolic diseases General Medicine Middle Aged medicine.disease Real life data Insulin Long-Acting Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Austria Female business |
Zdroj: | Diabetes research and clinical practice. 115 |
ISSN: | 1872-8227 |
Popis: | Aims To analyse time trends of antihyperglycaemic therapy and glycaemic control in adult subjects with type 1, or type 2 diabetes between 2002 and 2014 in Germany/Austria. Methods 184,864 adults with diabetes (35,144 type 1 diabetes (T1D), 149,720 type 2 diabetes (T2D)) from the DPV-database documented between 2002 and 2014 were included. Regression models were applied for antihyperglycaemic therapy in T2D (non-pharmacological, OADs only, insulin±OADs), insulin therapy in T1D (CT, ICT, CSII) and T2D (BOT, SIT, CT, ICT, CSII), for the use of insulin analogues, and for glycaemic control (HbA 1C , severe hypoglycaemia), adjusting for confounders sex, age, and diabetes duration. Results In T1D, CT (2002:19.7%; 2014:16.0%) and ICT (2002:66.8%; 2014:52.4%) decreased, while CSII increased from 13.5% to 31.5%. In T2D, non-pharmacological treatment became less frequent (2002:36.0%, 2014:21.8%), the use of OADs (2002:19.3%, 2014:28.9%) and insulin±OADs (2002:44.6%, 2014:49.4%) increased. BOT increased from 7.9% to 18.9%, SIT decreased from 12.0% to 8.3%. ICT slightly increased (2002:44.0%, 2014:45.3%), CT decreased (2002:35.8%, 2014:27.2%). Insulin analogues were used more frequently in T1D (rapid-acting:2002:46.8%, 2014:84.8%; long-acting:2002:26.0%, 2014:54.8%) and in T2D (rapid-acting:2002:26.0%, 2014:43.5%; long-acting:2002:13.7%, 2014:53.6%). Until 2011, HbA 1C increased in T1D and T2D, but then decreased again. High variability in the rate of hypoglycaemia was observed. Conclusions This observational study indicates an increased use of insulin pumps in T1D. In T2D, non-pharmacological therapy decreased, and insulin therapy, particular as BOT, rose. An increase in the use of rapid- and long-acting insulin analogues was present in both patient-groups. Time trend was less clear in glycaemic control. |
Databáze: | OpenAIRE |
Externí odkaz: |